PEMBROLIZUMAB

Course overview

PEMBROLIZUMAB IS A MEDICATION USED IN THE MANAGEMENT AND TREATMENT OF VARIOUS ONCOLOGIC CONDITIONS. IT IS IN THE CANCER IMMUNOTHERAPY CLASS OF DRUGS. THIS ACTIVITY WILL HIGHLIGHT PEMBROLIZUMAB'S MECHANISM OF ACTION, INDICATIONS, ADVERSE EVENT PROFILE, AND OTHER KEY FACTORS (E.G., NON-APPROVED INDICATIONS CURRENTLY IN CLINICAL TRIALS, ADMINISTRATION, DOSING, MONITORING, AND RELEVANT INTERACTIONS) PERTINENT FOR MEMBERS OF THE INTERPROFESSIONAL TEAM IN THE MANAGEMENT OF PATIENTS WITH ADVANCED CANCERS.